Skip to content
Screener

TG Therapeutics TGTX Other Research And Development Expense

Other Research And Development Expense at other companies

Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$1.98M-36.4%
OS Therapies logo
OS TherapiesOSTX
$0—
RFL
Rafael Holdings, Inc.RFL
$22K-51.1%
CTO
Citius Oncology, Inc.CTOR
$469K-2.3%
TG Therapeutics logo
TG TherapeuticsTGTX
$87.27M+218%
TG Therapeutics logo
TG TherapeuticsTGTX
$87.27M+218%

Other financials

Income statement

See full
Revenue$240.3M+70.3%
Gross profit$199.1M+62.9%
Operating income$21.7M-37.8%
Net income$7.8M-72.4%
EPS (diluted)$0.05-70.6%

Balance sheet

See full
Cash & equivalents$482.6M+274%
Total debt$754.4M+197%
Total equity$604.1M+119%
Total assets$1.6B+133%

Cash flow

See full
Operating cash flow$39.3M—
CapEx$293.0K+598%
Free cash flow$39.0M—

Valuation

See full
Market cap$7.64B+73.6%
Enterprise value$7.91B+74.9%
P/E17.3×-55.5×
P/S9.6×-0.1×

Profitability

See full
Gross margin82.4%-4.6pp
Operating margin17.1%-1.9pp
Net margin55.2%+41.9pp
FCF margin-6,328.4%+4,773pp

Returns & leverage

See full
Return on equity100.3%+73.6pp
Debt / equity1.2×+0.3×
Current ratio4.3×+0.4×

Where this comes from

Reported directly by TG Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.

The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:01 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001437749-26-025955
Line itemThree months ended / June 30, 2026Three months ended / June 30, 2025Six months ended / June 30, 2026Six months ended / June 30, 2025
Cost of revenue41,19418,93874,70434,479
Research and development:
Stock-based compensation8,0704,31812,9457,649
Other research and development87,26727,464130,78870,495
Total research and development95,33731,782143,73378,144
Selling, general and administrative:
Stock-based compensation19,80512,04434,88023,684
Other selling, general and administrative62,32543,541135,46782,232

Document

FAQ

What is TG Therapeutics's other research and development expense?
TG Therapeutics (TGTX) reported other research and development expense of $87.27M in Q2 2026.
How has TG Therapeutics's other research and development expense changed year-over-year?
TG Therapeutics's other research and development expense increased by 217.8% year-over-year, from $27.46M to $87.27M.
What is the long-term trend for TG Therapeutics's other research and development expense?
Over 4 years (2021 to 2025), TG Therapeutics's other research and development expense has grown at a -7.8% compound annual growth rate (CAGR), from $198.53M to $143.6M.
What does other research and development expense mean?
This represents research and development expenditures that are not categorized under specific line items like non-cash compensation. It typically includes clinical trial costs, laboratory supplies, and external research service fees.

Ask your AI about TG Therapeutics's other research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude